共 37 条
Cutting edge:: Novel priming of tumor-speciftic immunity by NKG2D-triggered NK cell-mediated tumor rejection and Th1-independent CD4+ T cell pathway
被引:40
作者:
Westwood, JA
[1
]
Kelly, JM
[1
]
Tanner, JE
[1
]
Kershaw, MH
[1
]
Smyth, MJ
[1
]
Hayakawa, Y
[1
]
机构:
[1] Peter MacCallum Canc Ctr, Sir Donald & Lady Trescowthick Labs, Canc Immunol Program, Melbourne, Vic 8006, Australia
关键词:
D O I:
10.4049/jimmunol.172.2.757
中图分类号:
R392 [医学免疫学];
Q939.91 [免疫学];
学科分类号:
100102 ;
摘要:
NKG2D is an activation receptor on NK cells and has been demonstrated as a primary cytotoxicity receptor for mouse NK cells. Primary rejection of class I-deficient RMA-S lymphoma cells expressing the NKG2D ligand, retinoic acid early inducible-1beta, was critically dependent upon NK cell perform and occurred independently of T cells NKG2D-triggered NK cell rejection of RMA-S-retinoic acid early inducible-1beta tumor primed a secondary tumor-specific T cell response mediated by both CD4(+) and CD8(+) T cells in the effector phase. Surprisingly, during the Priming phase, CD4(+) T cells, but not CD8(+) T cells, were also required to generate this secondary T cell immunity; however, T cell priming was independent of Th1 cytokines, such as IFN-gamma and IL-12. These data imply a novel pathway for priming T cell immunity, that is, stimulated upon NK cell-mediated cytotoxicity of NKG2D ligand-expressing tumor cells, dependent upon CD4(+) T cells in the primary phase, and independent of conventional Th1-type immunity.
引用
收藏
页码:757 / 761
页数:5
相关论文